Mok CC , Ho CT , Chan KW , Lau CS , Wong RW . Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine . Arthritis Rheum2002; 46: 1003–1013 .
2.
Illei GG , Takada K , Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies . Arthritis Rheum2002; 46: 995–1002 .
3.
Houssiau FA , Vasconcelos C , D'Cruz D et al and the Euro-Lupus Nephritis Trial Group . Efficacy and safety of a short-course intravenous pulse cyclophosphamide regimen in proliferative lupus nephritis: interim analysis of the Euro-Lupus Nephritis Trial. Arthritis Rheum (in press).
4.
Brodsky RA , Sensenbrenner LL , Jones RJ . Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation . Blood1996; 87: 491–494 .
5.
Brodsky RA , Sensenbrenner LL , Smith BD et al. Durable treatmentfree remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia . Ann Intern Med2001; 135: 477–483 .
6.
Brodsky RA , Petri M , Smith BD et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease . Ann Intern Med1998; 129: 1031–1035 .
7.
Gladstone DE , Prestrud AA , Pradhan A et al. High-dose cyclophosphamide for severe SLE . Lupus2002; 7: 405–410 .
8.
Amft N , D'Cruz D . Postchemotherapy connective tissue diseases—more than just rheumatism?Lupus1996; 5: 255–256 .
9.
Perrotta S , Locatelli F , La Manna A , Cennamo L , De Stefano P , Nobili B . Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus . Br J Haematol2002; 116: 465–467 .
10.
Chan TM , Li FK , Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group . New Engl J Med2000; 343: 1156–1162 .